Molecular Testing and Treatment Strategies in RET-Rearranged NSCLC Patients: Stay on Target to Look Forward

被引：3

作者：

Reale, Maria Lucia ^{[1
]}

Bertaglia, Valentina ^{[1
]}

Listi, Angela ^{[1
]}

Novello, Silvia ^{[1
]}

Passiglia, Francesco ^{[1
]}

机构：

[1] Univ Turin, S Luigi Gonzaga Hosp, Dept Oncol, I-10043 Orbassano, Italy

来源：

JOURNAL OF MOLECULAR PATHOLOGY | 2022年 / 3卷 / 01期

关键词：

RET; NSCLC; selpercatinib; pralsetinib; next-generation sequencing; acquired resistance; CELL LUNG-CANCER; TYROSINE KINASE-ACTIVITY; ACQUIRED-RESISTANCE; OPEN-LABEL; FUSION; SELPERCATINIB; INHIBITOR; MUTATIONS; PRALSETINIB; VANDETANIB;

D O I：

10.3390/jmp3010003

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

RET alterations are recognized as key oncogenic drivers in different cancer types, including non-small cell lung cancer (NSCLC). Multikinase inhibitors (MKIs) with anti-RET activities resulted in variable efficacy with significant toxicities because of low target specificity. Selective RET kinase inhibitors, such as pralsetinib and selepercatinib, demonstrated high efficacy and favorable tolerability in advanced RET-rearranged NSCLC patients, leading to their introduction in the clinical setting. Among the different approaches available for the identification of RET rearrangements, next-generation sequencing (NGS) assays present substantial advantages in terms of turnaround time and diagnostic accuracy, even if potentially limited by accessibility issues. The recent advent of novel effective targeted therapies raises several questions regarding the emergence of resistance mechanisms and the potential ways to prevent/overcome them. In this review, we discuss molecular testing and treatment strategies to manage RET fusion positive NSCLC patients with a focus on resistance mechanisms and future perspectives in this rapidly evolving scenario.

引用

页码：24 / 37

页数：14

共 79 条

[11]

clinicaltrials.gov, Study of TPX-0046, A RET/SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations

[12]

clinicaltrials.gov, A Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients With Resectable Stages II-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations

[13] Emergence of a RET V804M Gatekeeper Mutation During Treatment With Vandetanib in RET-Rearranged NSCLC [J].

Dagogo-Jack, Ibiayi ;

Stevens, Sara E. ;

Lin, Jessica J. ;

Nagy, Rebecca ;

Ferris, Lorin ;

Shaw, Alice T. ;

Gainor, Justin F. .

JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (11) :E226-E227

[14] KIF5B-RET Oncoprotein Signals through a Multi-kinase Signaling Hub [J].

Das, Tirtha Kamal ;

Cagan, Ross Leigh .

CELL REPORTS, 2017, 20 (10) :2368-2383

[15] Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer [J].

Drilon, A. ;

Oxnard, G. R. ;

Tan, D. S. W. ;

Loong, H. H. F. ;

Johnson, M. ;

Gainor, J. ;

McCoach, C. E. ;

Gautschi, O. ;

Besse, B. ;

Cho, B. C. ;

Peled, N. ;

Weiss, J. ;

Kim, Y. -J. ;

Ohe, Y. ;

Nishio, M. ;

Park, K. ;

Patel, J. ;

Seto, T. ;

Sakamoto, T. ;

Rosen, E. ;

Shah, M. H. ;

Barlesi, F. ;

Cassier, P. A. ;

Bazhenova, L. ;

De Braud, F. ;

Garralda, E. ;

Velcheti, V. ;

Satouchi, M. ;

Ohashi, K. ;

Pennell, N. A. ;

Reckamp, K. L. ;

Dy, G. K. ;

Wolf, J. ;

Solomon, B. ;

Falchook, G. ;

Ebata, K. ;

Nguyen, M. ;

Nair, B. ;

Zhu, E. Y. ;

Yang, L. ;

Huang, X. ;

Olek, E. ;

Rothenberg, S. M. ;

Goto, K. ;

Subbiah, V. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (09) :813-824

[16]

Drilon A, 2019, ANN ONCOL, V30, P190

[17] Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers [J].

Drilon, A. ;

Bergagnini, I. ;

Delasos, L. ;

Sabari, J. ;

Woo, K. M. ;

Plodkowski, A. ;

Wang, L. ;

Hellmann, M. D. ;

Joubert, P. ;

Sima, C. S. ;

Smith, R. ;

Somwar, R. ;

Rekhtman, N. ;

Ladanyi, M. ;

Riely, G. J. ;

Kris, M. G. .

ANNALS OF ONCOLOGY, 2016, 27 (07) :1286-1291

[18]

Drilon A, 2018, NAT REV CLIN ONCOL, V15, P151, DOI [10.1038/nrclinonc.2017.175, 10.1038/nrclinonc.2017.188]

[19] Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial [J].

Drilon, Alexander ;

Rekhtman, Natasha ;

Arcila, Maria ;

Wang, Lu ;

Ni, Andy ;

Albano, Melanie ;

Van Voorthuysen, Martine ;

Somwar, Romel ;

Smith, Roger S. ;

Montecalvo, Joseph ;

Plodkowski, Andrew ;

Ginsberg, Michelle S. ;

Riely, Gregory J. ;

Rudin, Charles M. ;

Ladanyi, Marc ;

Kris, Mark G. .

LANCET ONCOLOGY, 2016, 17 (12) :1653-1660

[20]

Gabrielle R., 2021, P AM ASS CANC RES AN

← 1 2 3 4 5 6 7 8 →